Conflict of Interest Disclosures

The public must have confidence in the integrity of the process by which the U.S. Preventive Services Task Force (USPSTF or Task Force) makes its recommendations. The reputations of the USPSTF members as highly regarded researchers, clinicians, and academic scholars contribute to this objective and must be protected if the USPSTF recommendation statements are to be accepted and implemented. It is also essential that Task Force deliberations benefit from members' vigorous exchange of perspectives that are derived from and shaped by the member's research and/or practice experiences.

The intent of requesting disclosure of any potential conflict of interest is to ensure that the USPSTF provides a balanced, independent, objective, and scientifically rigorous product (including its recommendation statements) by understanding other interests that could potentially influence the work and decisionmaking of its members. The USPSTF requires each member to disclose all information regarding any possible financial and nonfinancial conflicts of interest prior to each meeting for all topics under development or that will be discussed at each meeting. Previous disclosures for continuing topics must also be updated to reflect changes in a member’s situation since the form was last completed.

Prior to each meeting or to new member appointment, all disclosures are reviewed by the Task Force Chairs according to the criteria specified in the USPSTF Procedure Manual and determined to be either Level 1, 2, or 3. The Task Force Chairs determine the final action on the member's eligibility to participate on a specific topic based on the nature and significance of the potential conflict.

  • Level 1 disclosures include nonfinancial disclosures that would not affect the judgment of a Task Force member. These disclosures do not require any action.
  • Level 2 disclosures include financial disclosures of $1,000 or less and nonfinancial disclosures that are relevant to a topic but not anticipated to affect the judgment of the Task Force member for that topic. These disclosures are announced at the Task Force meeting, but do not limit the Task Force member’s participation in the topic process.
  • Level 3 disclosures include financial disclosures of a larger amount and significant nonfinancial disclosures that may affect the Task Force member's view on the topic. Actions for Level 3 disclosures vary according to the nature of the conflict, and may include preventing the member from serving as lead of a topic or on the workgroup of a topic, preventing the member from serving as a primary spokesperson for a topic, or preventing the member from taking part in all topic activities. As all new Task Force members are reviewed for conflicts prior to joining the Task Force, Level 3 disclosures are uncommon.

All decisions are kept on file. The USPSTF Procedure Manual provides a complete description of the criteria for each level and range of possible recommended actions.

 

Level 3 Disclosures for Current USPSTF Members

Karina W. Davidson:

Topic: Behavioral Counseling to Promote Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Risk Factors

Level 3 Disclosure: Dr. Davidson has a grant with the National Institute on Aging to study physical activity promotion to foster successful aging.

Date of Disclosure: March 2021

Action: Dr. Davidson may participate in the topic workgroup and deliberate and vote on the topic.

Carol M. Mangione: 

Topic: Screening for Prediabetes and Type 2 Diabetes

Level 3 Disclosure: Dr. Mangione has substantial experience and research expertise in the area of diabetes care. She has received multiple grants and authored multiple publications related to this topic. A majority of her work is related to treatment of diabetes.

Date of Disclosure: August 2018

Action: Dr. Mangione may participate in the topic workgroup and deliberate and vote on this topic.

Michael J. Barry:

Topic: Statin Use for Primary Prevention of Cardiovascular Disease in Adults

Level 3 Disclosure: Dr. Barry has a publication on this topic in which he discussed the prior USPSTF recommendation. This publication is in the EPC report.

Date of Disclosure: August 2021 

Action: Dr. Barry may participate in the topic workgroup and deliberate and vote on this topic.

Michael Cabana:

Topic: Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer

Level 3 Disclosure: Dr. Cabana been an investigator on two National Institutes of Health funded studies related to vitamin D.

Date of Disclosure: March 2020

Action: Dr. Cabana may participate in the topic workgroup and deliberate and vote on the topic.

Aaron B. Caughey: 

None

Esa M. Davis:

None

Katrina A. Donahue:

Topic: Screening for Prediabetes and Type 2 Diabetes

Level 3 Disclosure: Dr. Donahue is an author of a previous systematic evidence review (2003) commissioned by the USPSTF related to this topic.

Date of Disclosure: March 2020

Action: Dr. Donahue may participate in the topic workgroup and deliberate and vote on the topic.

Chyke A. Doubeni:

None

Martha Kubik:

None

Li Li:

Topic: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Level 3 Disclosure: Dr. Li has funded research evaluating biomarkers for risk stratification in colon cancer prevention using aspirin.

Date of Disclosure: March 2021

Action: Dr. Li may participate in the topic workgroup and deliberate and vote on the topic.

Gbenga Ogedegbe:

Topic: Behavioral Counseling to Promote Healthy Diet and Physical Activity for CVD Prevention in Adults Without Known Risk Factors

Level 3 Disclosure: Dr. Ogedegbe has a study included in the EPC report for this topic.

Date of Disclosure: March 2021

Action: Dr. Ogedegbe may participate in the topic workgroup and deliberate and vote on the topic.

Lori Pbert:

None

Michael Silverstein:

Topic: Screening for Depression, Anxiety, and Suicide Risk in Adults

Level 3 Disclosure: Dr. Silverstein is an investigator on a National Institute of Health funded project related to this topic.

Date of Disclosure: July 2020

Action: Dr. Silverstein may participate in the topic workgroup and deliberate and vote on the topic.

---------------------------

Topic: Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents

Level 3 Disclosure: Dr. Silverstein is an investigator on a National Institute of Health funded project related to this topic.

Date of Disclosure: July 2020

Action: Dr. Silverstein may participate in the topic workgroup and deliberate and vote on the topic.

James Stevermer:

Topic: Screening for Chronic Obstructive Pulmonary Disease

Level 3 Disclosure: Dr. Stevermer is an author on the American Academy of Family Physicians guideline on management of acute exacerbations of chronic obstructive pulmonary disease.

Date of Disclosure: March 2021

Action: Dr. Stevermer may participate in the topic workgroup and deliberate and vote on the topic.

Chien-Wen Tseng:

None

John B. Wong:

Topic: Behavioral Counseling to Promote Healthy Diet and Physical Activity for CVD Prevention in Adults Without Known Risk Factors

Level 3 Disclosure: Dr. Wong has a grant and a publication to study nutrition policies to reduce colorectal cancer incidence and mortality.

Date of Disclosure: March 2020

Action: Dr. Wong may participate in the topic workgroup and deliberate and vote on the topic.

---------------------------

Topic: Screening for Prediabetes and Type 2 Diabetes

Level 3 Disclosure: Dr. Wong has multiple poster presentations and abstract publications related to this topic.

Date of Disclosure: March 2020

Action: Dr. Wong may participate in the topic workgroup and deliberate and vote on the topic.

 

Current as of: August 2021
Internet Citation: Conflict of Interest Disclosures. U.S. Preventive Services Task Force. August 2021.